• September 19, 2016

    Press Release Spotlight

    Stealth BioTherapeutics Reports Elamipretide Improved Skeletal Muscle Bioenergetics in the Elderly

    Read the full article

    Trial evaluating treatment with investigational drug, elamipretide, demonstrated improved mitochondrial function by increasing energy production after single treatment BOSTON – September 19, 2016 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing investigational drugs to treat mitochondrial dysfunction, today announced results from the MOTION Trial. This clinical trial evaluated the systemic delivery of elamipretide on… Continue Reading >

    Read the full Press Release
  • September 12, 2016

    Press Release Spotlight

    Stealth BioTherapeutics Initiates Phase 2 Study of Elamipretide in Primary Mitochondrial Disease

    Read the full article

    BOSTON – September 12, 2016 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing investigational drugs to treat mitochondrial dysfunction, today announced the initiation of a longitudinal extension trial for evaluating elamipretide in primary mitochondrial disease. The study, MMPOWER-2, will be limited to patients who completed the initial MMPOWER Phase 2 study. Positive data from MMPOWER were announced in June 2016 showing statistically significant improvement in distance walked in six minutes.

    Read the full Press Release
  • September 6, 2016

    Press Release Spotlight

    Stealth BioTherapeutics to Participate in Upcoming Investor Conferences

    Read the full article

    BOSTON – September 6, 2016 – Stealth BioTherapeutics, a clinical-stage biopharmaceutical company developing investigational drugs to treat mitochondrial dysfunction, today announced that Stealth Chief Executive Officer Reenie McCarthy will participate in three upcoming investor conferences.

    Read the full Press Release

Stealth BioTherapeutics Reports Elamipretide Improved Skeletal Muscle Bioenergetics in the Elderly

Trial evaluating treatment with investigational drug, elamipretide, demonstrated improved mitochondrial function by increasing energy production after single treatment BOSTON – September 19, 2016 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing investigational drugs to treat mitochondrial dysfunction, today announced results from the MOTION Trial. This clinical trial evaluated the systemic delivery of elamipretide on… Continue Reading >

Stealth BioTherapeutics Initiates Phase 2 Study of Elamipretide in Primary Mitochondrial Disease

BOSTON – September 12, 2016 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing investigational drugs to treat mitochondrial dysfunction, today announced the initiation of a longitudinal extension trial for evaluating elamipretide in primary mitochondrial disease. The study, MMPOWER-2, will be limited to patients who completed the initial MMPOWER Phase 2 study. Positive data from MMPOWER were announced in June 2016 showing statistically significant improvement in distance walked in six minutes.

Stealth BioTherapeutics Initiates Two Phase 2 Trials Evaluating Elamipretide for the Treatment of Heart Failure

BOSTON – June 27, 2016 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing investigational drugs to treat mitochondrial dysfunction, today announced the initiation of two Phase 2 studies evaluating elamipretide in heart failure: PROGRESS-HF in patients with heart failure with reduced ejection fraction and RESTORE-HF in those with preserved ejection fraction. Top-line data from each are expected in the second half of 2017.

Stealth BioTherapeutics Reports Positive Elamipretide Data in First-Of-Its-Kind Primary Mitochondrial Myopathy Trial

BOSTON – June 17, 2016 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing investigational drugs to treat mitochondrial dysfunction, today announced the presentation of positive results from MMPOWER, a Phase 2 trial evaluating the systemic delivery of elamipretide for the treatment of primary mitochondrial myopathy, or muscle weakness, in patients with a genetically confirmed mitochondrial disease. The findings demonstrated statistically significant improvements with elamipretide in distance walked in six minutes, the study’s primary efficacy endpoint and an accepted measurement of functional exercise capacity.